• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comparison of Etest to Broth Microdilution for Testing of Susceptibility of Pseudomonas aeruginosa to Ceftolozane-Tazobactam.

作者信息

Flynt Lauren K, Veve Michael P, Samuel Linoj P, Tibbetts Robert J

机构信息

Henry Ford Hospital, Detroit, Michigan, USA.

Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.

出版信息

J Clin Microbiol. 2016 Dec 28;55(1):334-335. doi: 10.1128/JCM.01920-16. Print 2017 Jan.

DOI:10.1128/JCM.01920-16
PMID:27795348
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5228249/
Abstract
摘要

相似文献

1
Comparison of Etest to Broth Microdilution for Testing of Susceptibility of Pseudomonas aeruginosa to Ceftolozane-Tazobactam.Etest法与肉汤微量稀释法用于检测铜绿假单胞菌对头孢他啶-阿维巴坦敏感性的比较。
J Clin Microbiol. 2016 Dec 28;55(1):334-335. doi: 10.1128/JCM.01920-16. Print 2017 Jan.
2
Retraction for Flynt et al., "Comparison of Etest to Broth Microdilution for Testing of Susceptibility of Pseudomonas aeruginosa to Ceftolozane-Tazobactam".
J Clin Microbiol. 2018 May 25;56(6). doi: 10.1128/JCM.00541-18. Print 2018 Jun.
3
In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study.在体外研究头孢洛扎/他唑巴坦对西班牙医疗机构分离的铜绿假单胞菌和肠杆菌科临床分离株的活性：CENIT 研究结果。
Int J Antimicrob Agents. 2015 Nov;46(5):502-10. doi: 10.1016/j.ijantimicag.2015.07.004. Epub 2015 Aug 10.
4
Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-Resistant Pseudomonas aeruginosa.成功使用头孢洛扎/他唑巴坦治疗由多重耐药铜绿假单胞菌引起的囊性纤维化肺部加重期
Pharmacotherapy. 2016 Oct;36(10):e154-e159. doi: 10.1002/phar.1825. Epub 2016 Sep 1.
5
Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).针对2011 - 12年在欧洲医院分离出的具有不同耐药模式的铜绿假单胞菌和肠杆菌科细菌测试头孢洛扎/他唑巴坦的抗菌活性。
J Antimicrob Chemother. 2014 Oct;69(10):2713-22. doi: 10.1093/jac/dku184. Epub 2014 Jun 10.
6
Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).头孢洛扎/他唑巴坦对欧洲和美国医院腹腔内和尿路感染分离的需氧革兰氏阴性菌的活性检测（2012 年）。
J Infect. 2014 Sep;69(3):266-77. doi: 10.1016/j.jinf.2014.04.004. Epub 2014 Apr 26.
7
Comparison of disc diffusion, Etest and broth microdilution for testing susceptibility of carbapenem-resistant P. aeruginosa to polymyxins.纸片扩散法、Etest法和肉汤微量稀释法检测耐碳青霉烯类铜绿假单胞菌对多黏菌素敏感性的比较。
Ann Clin Microbiol Antimicrob. 2007 Aug 15;6:8. doi: 10.1186/1476-0711-6-8.
8
In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa in the planktonic and biofilm states.头孢他啶/他唑巴坦对浮游态和生物被膜态铜绿假单胞菌临床分离株的体外活性。
Diagn Microbiol Infect Dis. 2016 Jul;85(3):356-359. doi: 10.1016/j.diagmicrobio.2016.02.014. Epub 2016 Feb 18.
9
Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).头孢洛扎/他唑巴坦对来自美国和欧洲医疗机构住院肺炎患者分离的革兰氏阴性细菌的活性研究（2012 年）。
Int J Antimicrob Agents. 2014 Jun;43(6):533-9. doi: 10.1016/j.ijantimicag.2014.01.032. Epub 2014 Mar 26.
10
Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.在感染体外药代动力学模型中研究头孢洛扎坦加他唑巴坦的药效学。
Antimicrob Agents Chemother. 2015 Nov 9;60(1):515-21. doi: 10.1128/AAC.00727-15. Print 2016 Jan.

引用本文的文献

1
Evaluation of activity of ceftolozane-tazobactam in combination with other classes of antibacterial agents against and -the EM200 study.头孢洛扎/他唑巴坦与其他类抗菌药物联合应用对[具体对象]的活性评估及EM200研究
New Microbes New Infect. 2021 Mar 19;41:100872. doi: 10.1016/j.nmni.2021.100872. eCollection 2021 May.
2
Verification Is an Integral Part of Antimicrobial Susceptibility Test Quality Assurance.验证是抗菌药物敏感性试验质量保证的一个组成部分。
J Clin Microbiol. 2020 Mar 25;58(4). doi: 10.1128/JCM.01986-19.
3
Multicenter Evaluation of the Etest Gradient Diffusion Method for Ceftolozane-Tazobactam Susceptibility Testing of Enterobacteriaceae and Pseudomonas aeruginosa.多中心评估 Etest 梯度扩散法检测肠杆菌科和铜绿假单胞菌对头孢他啶-他唑巴坦的药敏试验。
J Clin Microbiol. 2018 Aug 27;56(9). doi: 10.1128/JCM.00717-18. Print 2018 Sep.
4
The Continued Value of Disk Diffusion for Assessing Antimicrobial Susceptibility in Clinical Laboratories: Report from the Clinical and Laboratory Standards Institute Methods Development and Standardization Working Group.纸片扩散法在临床实验室评估抗菌药物敏感性中的持续价值：来自临床和实验室标准协会方法研发和标准化工作组的报告。
J Clin Microbiol. 2018 Jul 26;56(8). doi: 10.1128/JCM.00437-18. Print 2018 Aug.
5
Performance of Ceftolozane-Tazobactam Etest, MIC Test Strips, and Disk Diffusion Compared to Reference Broth Microdilution for β-Lactam-Resistant Pseudomonas aeruginosa Isolates.头孢他啶-他唑巴坦 Etest、MIC 测试条和纸片扩散法与参考肉汤微量稀释法检测耐β-内酰胺铜绿假单胞菌分离株的性能比较。
J Clin Microbiol. 2018 Feb 22;56(3). doi: 10.1128/JCM.01633-17. Print 2018 Mar.
6
Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and Pseudomonas aeruginosa.碳青霉烯类耐药肠杆菌科细菌和铜绿假单胞菌中头孢他啶-阿维巴坦和头孢唑南-他唑巴坦药敏检测方法的验证。
J Clin Microbiol. 2018 Jan 24;56(2). doi: 10.1128/JCM.01093-17. Print 2018 Feb.
7
Development of MAST: A Microscopy-Based Antimicrobial Susceptibility Testing Platform.MAST 的研发：一种基于显微镜的抗菌药物敏感性测试平台。
SLAS Technol. 2017 Dec;22(6):662-674. doi: 10.1177/2472630317727721. Epub 2017 Aug 24.

本文引用的文献

1
New β-Lactamase Inhibitors in the Clinic.临床中的新型β-内酰胺酶抑制剂
Infect Dis Clin North Am. 2016 Jun;30(2):441-464. doi: 10.1016/j.idc.2016.02.007.
2
Emerging Resistance, New Antimicrobial Agents  …  but No Tests! The Challenge of Antimicrobial Susceptibility Testing in the Current US Regulatory Landscape.新出现的耐药性、新的抗菌药物……但没有检测！当前美国监管格局下抗菌药物敏感性检测面临的挑战。
Clin Infect Dis. 2016 Jul 1;63(1):83-8. doi: 10.1093/cid/ciw201. Epub 2016 Mar 29.
3
Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis.医院获得性耐药和多重耐药铜绿假单胞菌感染的临床和经济后果：系统评价和荟萃分析。
Antimicrob Resist Infect Control. 2014 Oct 20;3(1):32. doi: 10.1186/2047-2994-3-32. eCollection 2014.
4
Accuracy of automated and manual systems for susceptibility testing of Pseudomonas aeruginosa to piperacillin and piperacillin-tazobactam.铜绿假单胞菌对哌拉西林和哌拉西林-他唑巴坦药敏试验的自动化和手动系统的准确性
New Microbiol. 2011 Jan;34(1):97-9. Epub 2011 Jan 15.
5
Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment.铜绿假单胞菌血流感染：恰当初始抗菌治疗的重要性
Antimicrob Agents Chemother. 2005 Apr;49(4):1306-11. doi: 10.1128/AAC.49.4.1306-1311.2005.
6
Comparison of two commercial systems (Vitek and MicroScan-WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients.两种商业系统（Vitek和MicroScan-WalkAway）对囊性纤维化患者分离出的铜绿假单胞菌进行药敏试验的比较。
Diagn Microbiol Infect Dis. 2001 Apr;39(4):257-60. doi: 10.1016/s0732-8893(01)00234-6.
7
Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients.抗菌治疗不足：住院患者预后的一个重要决定因素。
Clin Infect Dis. 2000 Sep;31 Suppl 4:S131-8. doi: 10.1086/314079.